ONE-IBC-GROUP
23.3.2022 10:02:14 CET | Business Wire | Press release
One IBC Group , an international corporate service provider with 12 years of experience and a global outreach, highlighted in its 2022 action plan that technology is going to be the company’s main focus of growth. Through digital transformation and innovation, One IBC Group believes not only its services and operations will drastically improve, but the whole industry will also benefit and change the way it traditionally works.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005053/en/
The quest for digital transformation
In recent years, a majority of businesses have shifted their focus on technology and innovation in order to improve operational efficiency and further connect their services to their customers. With the help of revolutionary technologies such as CRMs, mobile apps, websites, etc., businesses have now been able to simplify their operations, tailor their products and services, and adapt to the various needs of their clients.
With that being said, not every industry can embark on the digitalized trend as quickly. Corporate service is a good example. Most, if not all, corporate service providers on the market right now are still using the same technology of 20 years ago. Though the services can be processed entirely remotely, and some can even be done automatically, no significant change has been made since then, while customer demand is increasing from time to time.
For an industry that has so much potential for digital transformation, corporate service is looking for a game-changing breakthrough.
One IBC Group’s plan to innovate
Since it was founded, One IBC Group has been using technology to remotely provide corporate services around the world. To be able to grow faster and compete with big players in the industry, the company decided to focus more on technology development.
In its 2022 action plan, One IBC Group emphasizes that digital transformation and innovation will be its primary mission. The plan set out a 5-year roadmap pinpointing each goal that needed to be achieved in a set time to upgrade the system and apply new technology. It includes automating the service order process, optimizing the operation procedures, building a client portal, incorporating software-as-a-service (SaaS) platforms, and constantly updating the whole system.
“It is no longer the future. The race for innovation is the new norm now,” said Jimmy Lee, CEO of One IBC Group. “With a solid technology foundation that we are having now, we believe One IBC Group can make a revolution in the corporate service industry.”
Prior to that, in 2021, One IBC Group had introduced its first mobile app . It was created with the goal of enhancing and improving client experience as well as introducing a new way to set up overseas businesses.
“This is just the beginning,” Jimmy said. “We are trying to provide more services and integrate them into our platforms as part of our ongoing development and extension, at the same time create a whole ecosystem for businesses to build their global expansion strategies.”
About One IBC Group
One IBC Group is a leading corporate service provider with global experience and delivery capabilities.
Since its beginning, One IBC Group has strived to provide global expansion strategies to entrepreneurs, investors, and business owners worldwide, with services ranging from company formation , trademark and license registration , to office and secretarial services. It has been building connections with international partners and using advanced technology to provide the best services to its clients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005053/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom